 |
市场调查报告书
NTRK遗传基因融合阳性癌症的开发平台医药品:市场机会的评估，市场趋势，流行病学的研究，开发中产品分析 (2020年下半年)NTRK Gene Fusion Positive Cancers Pipeline Drugs - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020 |
||||||
| 出版商 | GervanoRA Data Services LLP | 商品编码 | 979839 | ||||
| 出版日期 | 内容资讯 | 英文 290 Pages  |
|||||
| 价格 |
|
||||||
| NTRK遗传基因融合阳性癌症的开发平台医药品:市场机会的评估，市场趋势，流行病学的研究，开发中产品分析 (2020年下半年) NTRK Gene Fusion Positive Cancers Pipeline Drugs - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020 | ||
| 出版日期: 2020年12月30日 | 内容资讯: 英文 290 Pages |
|
本报告提供全球NTRK融合遗传基因阳性固体癌治疗药的开发平台医药品的市场相关分析，疾病概要和疫情趋势预测，未满足需求与市场机会，主要的资本交易的趋势 (M&A，事业合作等)，开发中产品的分析与临床实验的进展，现在、未来的竞争环境，主要企业的SWOT分析，新企业的简介与市场机会等资讯汇整，为您概述为以下内容。
GervanoRA's pipeline analysis and opportunity assessment report "NTRK Gene Fusion Cancers - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020" provides detailed analytics on the Epidemiology of NTRK Gene Fusion Cancers in different regions worldwide through a keen full assessment on historical and global trends of prevalence and incidence of NTRK gene fusion-positive cancers. Based on a literature survey and further validation through the KOL process, the report emphasizes finding out the affected population with NTRK gene fusion-positive cancers by geography (US, Europe, and Worldwide) and by majorly affected cancer types. The report even provides insights on TRK Inhibitors' foreseen market opportunities considering the TRK Inhibitor therapies are the only option to treat NTRK gene fusion-positive cancers. Report further analyzed and assessed the total forecasted market into two portions considering broader scope the TRK Inhibitors to treat indications like Neurodegenerative Diseases, Gastrointestinal Diseases and addiction conditions other than NTRK gene fusion-positive cancers. The report outlines how many people can undergo TRK Inhibitor therapies by 2029, and potential market value of NTRK gene fusion-positive cancers, and the market value of TRK Inhibitors meant to treat other indications other than NTRK gene fusion-positive cancers.
TRK Inhibitors pipeline molecules have been analysed for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitor drugs development pipeline.
The report has been divided into segments like TRK InhibitorsTherapies Overview and Epidemiological Studies, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the TRK Inhibitors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitors drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target, Pipeline Analytics by Indication and Pipeline Analytics by Company Type.
The report has covered more than 50 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:
Epidemiological Studies of NTRK Gene Fusion Positive Cancers
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.
